title: Hyalonect in the treatment of pseudarthrosis.
abstract: OBJECTIVE
  The aim of this study was to evaluate union rates and complications of Hyalonect, a knitted mesh composed of HYAFF, a benzyl ester of hyaluronic acid, and a naturally occurring constituent of the extracellular matrix, for the treatment of pseudarthrosis.
  
  
  METHODS
  The study included 11 patients (8 male, 3 female; mean age: 44.6 years; range: 23 to 57 years) operated for pseudarthrosis using Hyalonect. Average time between initial treatment and surgical procedure was 12.9 (range: 8 to 48) months. Pseudarthrosis of the tibia, femur and humerus was present in 4, 2 and 5 patients, respectively. All patients had undergone prior surgery (1 to 6 times). Each patient underwent open reduction and internal fixation. Allograft was applied to the pseudarthrosis area and covered with Hyalonect. Mean follow up period was 31 (range: 12 to 48) months.
  
  
  RESULTS
  Union was achieved in all patients after an average of 6 (range: 4 to 8) months. One patient had a discharge for two weeks. Another developed an infection which responded well to appropriate antibiotic treatment. No malunion or implant failure was observed. One patient with pre-existing radial nerve palsy maintained the condition.
  
  
  CONCLUSIONS
  Use of Hyalonect appears to be a safe method with a positive impact on union in the surgical treatment of pseudarthrosis, particularly in the absence of any infection.
authors: Department of Orthopedics and Traumatology, Okmeydanı Training and Research Hospital, Istanbul, Turkey.
authors: Ali Cağri
authors: AC
authors: Tekin
authors: Cem Zeki
authors: CZ
authors: Esenyel
authors: Murat
authors: M
authors: Cakar
authors: Meltem
authors: M
authors: Esenyel
authors: Yusuf
authors: Y
authors: Ozcan
authors: Mehmet Selçuk
authors: MS
authors: Saygili
mesh_terms: D000328:Adult; D064591:Allografts; D005260:Female; D005269:Femur / Q000601:surgery; D005500:Follow-Up Studies; D005593:Fracture Fixation, Internal / Q000379:methods; D017102:Fracture Healing; D006801:Humans; D006811:Humerus / Q000601:surgery; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011542:Pseudarthrosis / Q000601:surgery*; D011826:Radial Nerve / Q000293:injuries; D016059:Range of Motion, Articular; D012086:Reoperation; D012307:Risk Factors; D013526:Surgical Mesh; D013977:Tibia / Q000601:surgery; D016896:Treatment Outcome; D055675:Viscosupplements / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D055675:Viscosupplements; C086358:hyaluronic acid benzyl ester; D006820:Hyaluronic Acid